Business
Update on the FRP Investigation
SkinBioTherapeutics plc has announced that FRP Advisory is nearing the completion of its forensic investigation, with a report expected for the Board in the coming days. Following a review of these findings and consultation with external advisors, the company will finalize its HY26 results and restate its unaudited FY25 results as soon as practicable. Disclaimer*
About this update from Skinbiotherapeutics Plc
SkinBioTherapeutics plc ("SkinBioTherapeutics" or "the Company" or the "Group") Update on the FRP Investigation 29 April 2026 - the Board of SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, announces that FRP Advisory is in the final stages of its forensic investigation and is expected to provide its report to the Board in the coming days. Once the Board has had the opportunity to review the findings, taken appropriate advice from its external advisers, and considered the regulatory and governance implications of the investigation, it will finalise the HY26 results with the restated (unaudited) FY25 results as soon as practicable. -Ends- For more information please contact: SkinBioTherapeutics plc Martin Hunt, Executive Chairman Rachel Parsonage, Interim CEO Emily Bertram, CFO [email protected] Singer Capital Markets (Nominated Adviser & Broker) Philip Davies James Todd Patrick Weaver +44 (0) 020 7496 3000 Vigo Consulting Melanie Toyne-Sewell Rozi Morris +44 (0) 20 7390 0230 [email protected] Notes to Editors About SkinBioTherapeutics plc SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester. The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix®) and food supplements that harness the gut-skin axis (AxisBiotix™). The cosmetic pillar has a partnership with Croda plc where SkinBiotix® is being used as an active skin ingredient with the Croda trade name, Zenakine™. The AxisBiotix™ pillar has a range of products targeting the symptoms of inflammatory skin conditions, being sold directly and via Amazon, and on the High Street in selected Superdrug Stores plc stores. The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skincare and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products. The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.SkinBioTherapeutics.com.
View stock analysis, news, and events for Skinbiotherapeutics Plc